Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: An open-label, nonrandomized study

Clinical Therapeutics

Volumn 36, Issue 7, 2014, Pages

  Mehta, Rashmi ^a   Hardes, Kelly ^b   Kelleher, Dennis ^a   Preece, Andrew ^b   Tombs, Lee ^c   Brealey, Noushin ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Synergy Statistics and Programming   (United Kingdom)

Author keywords

chronic obstructive pulmonary disease; GSK573719; long acting muscarinic antagonist; umeclidinium; vilanterol

Indexed keywords

CYTOCHROME P450 2D6; UMECLIDINIUM; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; DRUG COMBINATION; QUINUCLIDINE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; UMECLIDINIUM PLUS VILANTEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER INHALER; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MODERATE HEPATIC IMPAIRMENT; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; LIVER DISEASE; MIDDLE AGED; URINE; YOUNG ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; DRUG SCREENING; DRUG URINE LEVEL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; BENZYL ALCOHOLS; CASE-CONTROL STUDIES; CHLOROBENZENES; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; QUINUCLIDINES; YOUNG ADULT;

EID: 84904813627     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.05.002     Document Type: Article

References (24)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management. html. Accessed May 2014.
2. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease: data and statistics, April 2013. http://www.cdc.gov/copd/data.htm. Accessed December 3, 2013.
3. A. Church, M. Beerahee, J. Brooks, R. Mehta, and P. Shah Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study BMC Pulm Med 14 2014 2
4. J.F. Donohue, A. Anzueto, and J. Brooks et al. A randomized, double-blind, dose-ranging study of the novel LAMA GSK573719 in patients with COPD Respir Med 106 2012 970 979
5. M. Decramer, F. Maltais, and G. Feldman et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients Respir Physiol Neurobiol 185 2013 393 399
6. R. Trivedi, N. Richard, R. Mehta, and A. Church Umeclidinium in patients with COPD: a randomised, placebo-controlled study Eur Respir J 43 2014 72 81
7. R. Tal-Singer, A. Cahn, and R. Mehta et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies Eur J Pharmacol 701 2013 40 48
8. G. Feldman, R.R. Walker, and J. Brooks et al. 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial Pulm Pharmacol Ther 25 2012 465 471
9. D.L. Kelleher, R.S. Mehta, and B.M. Jean-Francois et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial PLoS One 7 2012 e50716
10. J.F. Donohue, M.R. Maleki-Yazdi, and S. Kilbride et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir Med 107 2013 1538 1546
11. D. Kelleher, S. Hughes, and R. Mehta et al. Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults Eur Respir J 40 Suppl 56 2012 384s Abstract
12. A. Cahn, R. Mehta, and A. Preece et al. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial Clin Drug Investig 33 2013 653 664
13. A.W. Harrell, S.K. Siederer, and J. Bal et al. Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans Drug Metab Dispos 41 2013 89 100
14. R. Kempsford, A. Allen, and J. Bal et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects Br J Clin Pharmacol 75 2013 1478 1487
15. R. Mehta, D. Kelleher, and A. Preece et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study Int J Chron Obstruct Pulmon Dis 8 2013 159 167
16. R. Verbeeck Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction Eur J Clin Pharmacol 64 2008 1147 1161
17. US Dept of Health and Human Services, Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072123.pdf. Accessed December 3, 2013.
18. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003122.pdf. Accessed December 3, 2013.
19. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. http://www.wma.net/en/ 30publications/10policies/b3/index.html. Accessed December 3, 2013.
20. International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1), 1996. http://www.ich.org/fileadmin/Public- Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf. Accessed December 3, 2013.
21. A. Cahn, R. Tal-Singer, and I.J. Pouliquen et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies Clin Drug Invest 33 2013 477 488
22. D. Kelleher, L. Tombs, and G. Crater et al. A placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects Am J Respir Crit Care Med 187 2013 A1487 Abstract
23. A. Allen, A. Davis, and K. Hardes et al. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination Clin Ther 34 2012 2316 2332
24. K. Woodhouse, and H.A. Wynne Age-related changes in hepatic function. Implications for drug therapy Drugs Aging 2 1992 243 255